Now in Tablets
A drug for treatment of chronic viral hepatitis C – the first Russian drug in the form of tablets, narlaprevir by R-Pharm is launched in the Russian market. A marketing authorization certificate has been obtained for it.
Narlaprevir is a new generation protease inhibitor. It is intended for treatment of chronic hepatitis C (genotype 1) in combination with other antiviral drugs. Inhibiting NS3-serine viral protease, narlaprevir prevents its replication in infected cells of host.
That effective, convenient drug was developed in cooperation with the Texas Liver Institute (USA) – a world leader in the field of hepatology. Preclinical and clinical studies were performed at scientific research clinical centers of Europe, USA and Russia.
Development of narlaprevir is being performed under support of the Federal Target Program “Development of Pharmaceutical and Healthcare Industry of the Russian Federation Until 2020 and Further”.